Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Pharmacy and Science

• Publication date

  2015-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/jps.24444PMID 25872915
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer.

  2016cited by this paper
• Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy

  2014cited by this paper
• Immunoglobulin G (IgG) Fab Glycosylation Analysis Using a New Mass Spectrometric High-throughput Profiling Method Reveals Pregnancy-associated Changes*

  2014cited by this paper
• Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297.

  2014cited by this paper
• Fc Receptors as Adaptive Immunoreceptors

  2014cited by this paper
• Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics.

  2014cited by this paper
• Modulation of Mannose and Asialoglycoprotein Receptor Expression Determines Glycoprotein Hormone Half-life at Critical Points in the Reproductive Cycle*

  2014cited by this paper
• Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies

  2014cited by this paper
• Glycosylation and Fc receptors.

  2014cited by this paper
• The Impact of Glycosylation on the Pharmacokinetics of a TNFR2:Fc Fusion Protein Expressed in Glycoengineered Pichia Pastoris

  2013cited by this paper
• General mechanism for modulating immunoglobulin effector function

  2013cited by this paper
• Tick bites and red meat allergy

  2013cited by this paper
• Therapeutic antibodies: market considerations, disease targets and bioprocessing.

  2013cited by this paper
• High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.

  2013cited by this paper
• Grow your own: Protalix BioTherapeutics produces drugs in carrot cells.

  2013cited by this paper
• Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors

  2013cited by this paper
• Obinutuzumab: First Global Approval

  2013cited by this paper
• The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study

  2013cited by this paper
• Antibody Glycosylation and Inflammation

  2013cited by this paper
• Challenges in O-glycan engineering of plants

  2012cited by this paper
• Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation

  2012cited by this paper
• Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques

  2012cited by this paper
• Mogamulizumab

  2012cited by this paper
• Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family.

  2012cited by this paper
• Revisiting the role of glycosylation in the structure of human IgG Fc.

  2012cited by this paper
• Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans

  2012cited by this paper
• Imiglucerase in the treatment of Gaucher disease: a history and perspective

  2012cited by this paper
• Translating basic mechanisms of IgG effector activity into next generation cancer therapies.

  2012cited by this paper
• Marketing approval of mogamulizumab

  2012cited by this paper
• Glycosylation profiles of therapeutic antibody pharmaceuticals.

  2011cited by this paper
• Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials.

  2011cited by this paper
• Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's).

  2011cited by this paper
• Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer.

  2011cited by this paper
• Acceptable changes in quality attributes of glycosylated biopharmaceuticals

  2011cited by this paper
• High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.

  2011cited by this paper
• Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies

  2011cited by this paper
• Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters.

  2011cited by this paper
• Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

  2011cited by this paper
• Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway

  2011cited by this paper
• The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose.

  2011cited by this paper
• Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.

  2010cited by this paper
• Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

  2010cited by this paper
• Naturally occurring glycan forms of human immunoglobulins G1 and G2.

  2010cited by this paper
• Transient expression of an IL-23R extracellular domain Fc fusion protein in CHO vs. HEK cells results in improved plasma exposure.

  2010cited by this paper
• Engineering host cell lines to reduce terminal sialylation of secreted antibodies

  2010cited by this paper
• A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs

  2010cited by this paper
• GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins

  2010cited by this paper
• Immunogenicity of therapeutics: a matter of efficacy and safety

  2010cited by this paper
• Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

  2010cited by this paper
• Expression systems for therapeutic glycoprotein production.

  2009cited by this paper
• Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

  2009cited by this paper
• GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.

  2009cited by this paper
• Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

  2009cited by this paper
• Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action.

  2009cited by this paper
• Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study

  2009cited by this paper
• Structure of the murine unglycosylated IgG1 Fc fragment.

  2009cited by this paper
• Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model

  2008cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008cited by this paper
• Terminal sugars of Fc glycans influence antibody effector functions of IgGs.

  2008cited by this paper
• Effector mechanisms of therapeutic antibodies against ErbB receptors.

  2008cited by this paper
• Anti-inflammatory actions of intravenous immunoglobulin.

  2008cited by this paper
• Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors

  2008cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: A carbohydrate of unique evolution and clinical relevance

  2008cited by this paper
• Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content.

  2008cited by this paper
• The effect of Fc glycan forms on human IgG2 antibody clearance in humans.

  2008cited by this paper
• Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins.

  2008cited by this paper
• Evidence for an Asialoglycoprotein Receptor on Nonparenchymal Cells for O-Linked Glycoproteins

  2008cited by this paper
• Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease.

  2008cited by this paper
• Dependence of antibody-mediated presentation of antigen on FcRn

  2008cited by this paper
• Glycosylation of Recombinant Antibody Therapeutics

  2008cited by this paper
• The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance.

  2008cited by this paper
• Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc

  2008cited by this paper
• Mucin-type O-glycosylation and its potential use in drug and vaccine development.

  2008cited by this paper
• Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function

  2008cited by this paper
• Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys.

  2007cited by this paper
• High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.

  2007cited by this paper
• Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.

  2007cited by this paper
• Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry.

  2007cited by this paper
• Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.

  2007cited by this paper
• Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

  2007cited by this paper
• The glycosylation and pharmacokinetics of CTLA4Ig produced in rice cells.

  2007cited by this paper
• FcRn: the neonatal Fc receptor comes of age

  2007cited by this paper
• The impact of glycosylation on the biological function and structure of human immunoglobulins.

  2007cited by this paper
• Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.

  2007cited by this paper
• Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion.

  2007cited by this paper
• Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC

  2006cited by this paper
• The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms.

  2006cited by this paper
• Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization.

  2006cited by this paper
• FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

  2006cited by this paper
• Optimization of humanized IgGs in glycoengineered Pichia pastoris

  2006cited by this paper
• Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

  2006cited by this paper
• Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria.

  2006cited by this paper
• Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces.

  2006cited by this paper
• Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

  2006cited by this paper
• Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa

  2006cited by this paper
• Capillary electrophoresis with laser-induced fluorescence detection for detailed studies on N-linked oligosaccharide profile of therapeutic recombinant monoclonal antibodies.

  2006cited by this paper
• Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody

  2006cited by this paper
• Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.

  2006cited by this paper
• Mechanisms in protein O-glycan biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: a review.

  2006cited by this paper

• Glycosylation control strategies for recombinant therapeutic proteins in CHO cells.

  2026cites this paper
• Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody

  2026cites this paper
• Near UV and Visible Light-Induced Degradation of IgG2: Photo-Fenton Reaction in Citrate Buffer.

  2026cites this paper
• Antigen binding triggers long-range conformational changes in monoclonal antibodies

  2026cites this paper
• Evolution of Immune Checkpoint Blockade in Metastatic NSCLC: A Narrative Review of Emerging Bispecific Antibodies and the Practical Challenges of Clinical Integration.

  2026cites this paper
• Targeting the epidermal growth factor receptor using IgM antibodies: toward next generation cancer immunotherapy

  2026cites this paper
• Development of cell lines producing recombinant therapeutic proteins, with denosumab as a case study

  2025cites this paper
• Structural determinants of IgG1-FcγRIIIa interaction: a comprehensive computational study

  2025cites this paper
• Highly Variable Aggregation and Glycosylation Profiles and Their Roles in Immunogenicity to Protein-Based Therapeutics.

  2025cites this paper
• Multiple analysis based on dual-mode anion-exchange chromatography strategy reveals significant impact of charge heterogeneity on structure and function of dulaglutide.

  2025cites this paper
• Immunogenicity Risk Assessment of Biotherapeutics Using an Ex Vivo B Cell Assay

  2025cites this paper
• Enzymatic Desialylation Enables Reliable Charge Variant Characterization of Highly Glycosylated and Sialylated Fc Fusion Proteins.

  2025cites this paper
• Does the Chimerization Process Affect the Immunochemical Properties of WNV-Neutralizing Antibody 900?

  2025cites this paper
• IgE based therapeutics are an emerging modality in cancer treatment

  2025cites this paper
• Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies

  2025cites this paper
• A predictive modular approach to constraint satisfaction under uncertainty - with application to glycosylation in continuous monoclonal antibody biosimilar production

  2025cites this paper
• Temporal Galactose‐Manganese Feeding in Fed‐Batch and Perfusion Bioreactors Modulates UDP‐Galactose Pools for Enhanced mAb Glycosylation Homogeneity

  2025cites this paper
• Role of N-glycosylation in structural stability and binding specificity of IL-1ra antagonist to it receptor: an efficient approach to engineer therapeutic proteins

  2025cites this paper
• Utilizing non-clonal CHO cell derived materials for preclinical studies of complex molecules

  2025cites this paper
• Humoral immune response to 10-valent pneumococcal conjugate vaccine (PCV10) in individuals with type 2 diabetes mellitus.

  2025cites this paper
• Computational analysis reveals non-consensus N-glycosylation sequons in antibody Fab region

  2025cites this paper
• Continuous glucose feedback control using Raman spectroscopy and deep learning models for biopharmaceutical processes

  2025cites this paper
• Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC

  2025cites this paper
• Characterizing and engineering post-translational modifications with high-throughput cell-free expression

  2025cites this paper
• Biopharmaceutical Analysis by HPLC: Practices and Challenges

  2025cites this paper
• Quality (Attributes) Over Quantity: Minimal Essential Quality Attributes for Determining Antibody Stability in Postproduction Handling Stability Studies.

  2025cites this paper
• Characterization of deglycosylated anti-cocaine mAb by differential scanning fluorimetry and fluorescence labeling

  2025cites this paper
• Optimizing Rituximab Glycosylation: Insights from Single-Use Bioreactor Cultivation

  2025cites this paper
• TNF-α in traumatic brain injury: a bidirectional effect in regulating neuroimmune and inflammatory responses

  2025cites this paper
• Fc-Engineered B7-H3 Antibody with Prolonged Serum Half-Life for Enhanced Cancer Therapy.

  2025cites this paper
• The importance of IgG N-glycosylation in Health, Disease, and Neonatal hemochromatosis

  2025cites this paper
• Regulated bioanalysis of antibody-drug conjugates using LC-MS.

  2025cites this paper
• Structural and epitope characterization of anti-DEFA5 monoclonal antibodies clones 1A8 and 4F5 for inflammatory bowel disease subtype diagnostics

  2025cites this paper
• Protein pellet sample preparation for the analysis of N-glycans of therapeutic proteins

  2025cites this paper
• Enhancing the Total Terminal Galactosylation of CHO Cell-Derived TNF-α Blocker-IgG1 Monoclonal Antibody Using Time-Dependent Galactose Supplementation

  2025influential citation
• Sialylation Impacts Separation of a Biotherapeutic by Capillary Gel Electrophoresis

  2025cites this paper
• The impact of Fc glycosylation on IgG susceptibility to hinge region chemical reduction: implications for the development of immunoassays

  2025cites this paper
• Perivascular Niche-Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment.

  2025cites this paper
• A robust label-free workflow for the immunoglobulin G subclass site-specific N-glycopeptides and the glycosylation of IgG 2 correlated with colorectal cancer.

  2025cites this paper
• Wheels turning: CHO cell modeling moves into a digital biomanufacturing era

  2025cites this paper
• Optimising Monoclonal Antibody Drug Development for Inflammatory Bowel Disease

  2025cites this paper
• Naturally acquired antibodies against 4 Streptococcus pneumoniae serotypes in Pakistani adults with type 2 diabetes mellitus

  2024cites this paper
• New Inhibitors of β‐1,4‐Galactosyltransferase I Discovered by Virtual Screening

  2024cites this paper
• Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications.

  2024cites this paper
• Cellulose functionalized magnetic beads for high throughput glycosylation analysis in biotherapeutic modalities

  2024cites this paper
• A first‐in‐human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults

  2024cites this paper
• LC-MS/MS-Based Site-Specific N-Glycosylation Analysis of VEGFR-IgG Fusion Protein for Sialylation Assessment Across IEF Fractions

  2024cites this paper
• Simple Endoglycosidase-assisted Peptide Mapping Workflow for Characterizing Non-consensus N-glycosylation in Therapeutic Monoclonal Antibodies.

  2024cites this paper
• Recent Advances in Labeling‐Based Quantitative Glycomics: From High‐Throughput Quantification to Structural Elucidation

  2024cites this paper
• Protein aggregation in the frozen state induced by dropping stress.

  2024cites this paper
• An examination of process models and model risk frameworks for pharmaceutical manufacturing

  2024cites this paper
• Analysis of Beyfortus® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention

  2024cites this paper
• In silico mediated workflow for rapid development of downstream processing: Orthogonal product-related impurity removal for a Fc-containing therapeutic.

  2024cites this paper
• CE-MS and CE-MS/MS for the multiattribute analysis of monoclonal antibody variants at the subunit level.

  2024cites this paper
• Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo

  2024cites this paper
• Sar1A overexpression in Chinese hamster ovary cells and its effects on antibody productivity and secretion.

  2024cites this paper
• Flux balance analysis and peptide mapping elucidate the impact of bioreactor pH on Chinese Hamster Ovary (CHO) cell metabolism and N-linked glycosylation in the Fab and Fc regions of the produced IgG

  2024cites this paper
• Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins

  2024cites this paper
• Structure-Based High-Efficiency Homogeneous Antibody Platform by Endoglycosidase Sz Provides Insights into Its Transglycosylation Mechanism

  2024cites this paper
• Efficient Expression of Functionally Active Aflibercept with Designed N-glycans

  2024cites this paper
• Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy

  2024cites this paper
• Enhancing recombinant antibody yield in Chinese hamster ovary cells

  2024cites this paper
• Escherichia coli and Pichia pastoris: microbial cell-factory platform for full-length IgG production

  2024cites this paper
• In-Membrane Enrichment and Peptic Digestion to Facilitate Analysis of Monoclonal Antibody Glycosylation.

  2024cites this paper
• Demonstration of a robust high cell density transient CHO platform yielding mAb titers of up to 2 g/L without medium exchange

  2024cites this paper
• Enhanced N-Glycan Profiling of Therapeutic Monoclonal Antibodies through the Application of Upper-Hinge Middle-Up Level LC-HRMS Analysis

  2024cites this paper
• Human IgG Subclasses Differ in the Structural Elements of Their N-Glycosylation

  2024cites this paper
• In silico evaluation of the role of Fab glycosylation in cetuximab antibody dynamics

  2024cites this paper
• Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies

  2024cites this paper
• Nanobodies: From High-Throughput Identification to Therapeutic Development

  2024cites this paper
• Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation.

  2024cites this paper
• The importance of IgG glycosylation—What did we learn after analyzing over 100,000 individuals

  2024cites this paper
• Rapid preparation of a glycan oxazoline and a homogeneously glycosylated antibody with an enzyme-immobilized monolithic column.

  2024cites this paper
• Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro

  2024cites this paper
• High enhancement of sensitivity and reproducibility in label-free SARS-CoV-2 detection with graphene field-effect transistor sensors through precise surface biofunctionalization control.

  2024cites this paper
• Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding Rapidly Characterize the Structural Polydispersity and Stability of an Fc-Fusion Protein.

  2024cites this paper
• Sialic acid O-acetylation patterns and glycosidic linkage type determination by ion mobility-mass spectrometry

  2023cites this paper
• Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc

  2023cites this paper
• From cell factories to patients: Stability challenges in biopharmaceuticals manufacturing and administration with mitigation strategies.

  2023cites this paper
• A novel hybrid bioprocess strategy addressing key challenges of advanced biomanufacturing

  2023cites this paper
• Expedited Evaluation of Conformational Stability-Heterogeneity Associations for Crude Polyclonal Antibodies in Response to Conjugate Vaccines.

  2023cites this paper
• An assessment of the impact of Raman based glucose feedback control on CHO cell bioreactor process development

  2023cites this paper
• Multi-Attribute Monitoring Method for Process Development of Engineered Antibody for Site-Specific Conjugation

  2023cites this paper
• What is the role of current mass spectrometry in pharmaceutical analysis?

  2023cites this paper
• Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies.

  2023cites this paper
• Glycosylation differences of an anti-VEGF monoclonal antibody (PRO-169) and its extensive comparison with Bevacizumab.

  2023cites this paper
• Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review

  2023cites this paper
• Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method

  2023cites this paper
• Effect of Fc core fucosylation and light chain isotype on IgG1 flexibility

  2023cites this paper
• LC/MS Assessment of Glycoform Clearance of a Biotherapeutic mAb in Rabbit Ocular Tissues.

  2023cites this paper
• Double Proteolysis for N- and O-glycan Analysis of Fc-fusion Protein Etanercept

  2023cites this paper
• Effects of various pine needle extracts on Chinese hamster ovary cell growth and monoclonal antibody quality

  2023cites this paper
• Cell factory engineering: Challenges and opportunities for synthetic biology applications

  2023cites this paper
• Study on antibody Fc-glycosylation for optimal effector functions.

  2023cites this paper
• IgY antibodies: The promising potential to overcome antibiotic resistance

  2023cites this paper
• Enhanced antibody-defucosylation capability of α-L-fucosidase by proximity-based protein fusion.

  2023cites this paper
• Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies

  2023cites this paper
• Temporal Effects of Galactose and Manganese Supplementation on Monoclonal Antibody N-Linked Glycosylation in Fed-Batch and Perfusion Bioreactor Operation

  2023cites this paper
• Integrating ultra-high performance liquid chromatography tandem mass spectrometry and imaged capillary isoelectric focusing for in-depth characterization of complex fusion proteins.

  2023cites this paper
• Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study

  2023cites this paper